Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 128   

Articles published

NVO 46.84 -0.21 (-0.45%)
price chart
Zacks Rating Update on Novo Nordisk A/S (ADR)
As much as 2 analysts have advised buy on Novo Nordisk A/S (ADR) (NYSE:NVO) with an average broker rating of 2. Research Analysts at Zacks has the counter a rating of 3, which implies that the firms recommendation is Neutral on the company.
Novo Nordisk A/S (ADR) Update: Investors Sell Shares on the Price Strength  Wall Street Pulse
Slumping Stcoks:Novo Nordisk A/S (ADR) (NVO), Goldman Sachs Group Inc (GS ...  Techsonian (press release)
Brokerage Firm Rating Disclosure Update on Novo Nordisk A/S (ADR)
Major Brokerage house, Commerbank downgrades its ratings on Novo Nordisk A/S (ADR) (NYSE:NVO). According to the latest information available, the shares are now rated Hold by the analysts at the agency.
Company Shares of Novo Nordisk A/S (ADR) Drops by -4.78%  Winston View
Novo Nordisk A/S (ADR) Witness Inflow of Net $1.32M  Markets Bureau
Merck & Co., Inc. (MRK) And Novo Nordisk A/S (ADR) (NVO) Join An Open ...
Merck & Co., Inc. (NYSE:MRK) and Novo Nordisk A/S (ADR) (NYSE:NVO) became the latest pharmaceutical companies to join the GPCR Consortium, which is working to explore the biology of proteins called G-protein coupled receptors.
Latest Updates on Novo Nordisk A/S (ADR) (NYSE:NVO)
The injectable drug is the second obesity treatment to be approved by the FDA this year; the first obesity-related treatment, approved in September, was Contrave, an oral medicine by Orexigen Therapeutics Inc. (NASDAQ:OREX).
Novo Nordisk (NVO) Searching For A New CEO  Bidness ETC
Related articles »  
Novo Nordisk A/S (ADR) Price Target Update
Novo Nordisk A/S (ADR) (NYSE:NVO): The mean short term price target for Novo Nordisk A/S (ADR) (NYSE:NVO) has been established at $58.52 per share.
Companies That Offer High Returns - Accenture Plc (NYSE:ACN), Novo Nordisk ...  Wall Street Observer
Share Price of Novo Nordisk A/S (ADR) Rally 3.14%
Shares of Novo Nordisk A/S (ADR) (NYSE:NVO) appreciated by 3.14% during the past week but lost 1.2% on a 4-week basis.
Stocks With High Return On Investment - Plug Power Inc(NASDAQ:PLUG), Novo ...  Wall Street Observer
Trending Stocks - Novo Nordisk (NVO), Aramark(ARMK), Voya Financial (VOYA ...  Techsonian (press release)
CHMP Gives Positive Opinion On Novo Nordisk's Obesity Drug Saxenda
Yesterday Novo Nordisk A/S (ADR) (NYSE:NVO) said that it has received a positive verdict from the Committee for Medicinal Products for Human Use (CHMP), for its obesity drug Saxenda.
Novo Nordisk A/S (ADR) Analyst Rating Update
Analysts at Zacks have given a Neutral rating on Novo Nordisk A/S (ADR) (NYSE:NVO) with a rating of 3. The counter has received an average rating of 2 from 2 brokerage firms.
McDonald's Corporation (MCD), Novo Nordisk A/S (ADR) (NVO), Colgate ...
Novo Nordisk A/S (ADR) (NYSE:NVO) also kept its spot in Mr. Simons' list. The $189 billion market cap healthcare company witnessed a 5% boost in the fund's exposure between April and June.
Novo Nordisk A/S (ADR) (NVO): A Company Solving The Global Diabetes Crisis ...
Novo Nordisk A/S (NYSE: NVO) is the undisputed global leader in the diabetes market. The company's impressive product portfolio is home to five of the world's 10 best-selling diabetes medications.
Related articles »